Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Amgen Inc (AMGN)

Amgen Inc (AMGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 190,441,936
  • Shares Outstanding, K 539,068
  • Annual Sales, $ 36,751 M
  • Annual Income, $ 7,711 M
  • EBIT $ 9,080 M
  • EBITDA $ 15,447 M
  • 60-Month Beta 0.47
  • Price/Sales 5.16
  • Price/Cash Flow 10.41
  • Price/Book 21.88

Options Overview Details

View History
  • Implied Volatility 33.83% (+2.07%)
  • Historical Volatility 21.11%
  • IV Percentile 88%
  • IV Rank 46.14%
  • IV High 50.37% on 04/08/25
  • IV Low 19.66% on 08/15/25
  • Expected Move (DTE 8) 11.65 (3.35%)
  • Put/Call Vol Ratio 0.90
  • Today's Volume 1,523
  • Volume Avg (30-Day) 6,057
  • Put/Call OI Ratio 0.75
  • Today's Open Interest 96,545
  • Open Int (30-Day) 100,467
  • Expected Range 335.67 to 358.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 35 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $4.74
  • Number of Estimates 10
  • High Estimate $5.21
  • Low Estimate $4.47
  • Prior Year $4.90
  • Growth Rate Est. (year over year) -3.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
344.95 +0.73%
on 03/20/26
381.74 -8.97%
on 03/03/26
-38.22 (-9.91%)
since 03/02/26
3-Month
318.21 +9.20%
on 01/05/26
391.29 -11.20%
on 03/02/26
+19.84 (+6.06%)
since 01/02/26
52-Week
261.43 +32.92%
on 05/14/25
391.29 -11.20%
on 03/02/26
+41.78 (+13.67%)
since 04/02/25

Most Recent Stories

More News
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy

- Collaboration with Amgen to explore the clinical potential of Zai Lab’s DLL3-targeting ADC, zocilurtatug pelitecan, in combination with Amgen’s IMDELLTRA ® ...

ZLAB : 20.61 (+1.33%)
AMGN : 346.31 (-1.97%)
REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS

Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention

AMGN : 346.31 (-1.97%)
2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds

2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds

AVGO : 312.78 (-0.23%)
GEV : 896.87 (+0.23%)
AMGN : 346.31 (-1.97%)
Biogen Stock: Is BIIB Outperforming the Healthcare Sector?

Biogen has outperformed its sector peers recently, and analysts remain moderately optimistic about the stock’s prospects.

XLV : 146.45 (-0.87%)
AMGN : 346.31 (-1.97%)
BIIB : 176.88 (-3.75%)
Q4 Earnings Highs And Lows: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks

Q4 Earnings Highs And Lows: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks

AMGN : 346.31 (-1.97%)
AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE

THOUSAND OAKS, Calif. , March 5, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Leerink Partners 2026 Global Healthcare Conference at 9:20 a.m. ET on Wednesday, March 11, 2026. Peter...

AMGN : 346.31 (-1.97%)
AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND

THOUSAND OAKS, Calif. , March 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the second quarter of 2026. The dividend...

AMGN : 346.31 (-1.97%)
2 Profitable Stocks with Solid Fundamentals and 1 Facing Headwinds

2 Profitable Stocks with Solid Fundamentals and 1 Facing Headwinds

AMP : 434.13 (-0.58%)
GDEN : 26.97 (+1.01%)
AMGN : 346.31 (-1.97%)
Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Although Regeneron Pharmaceuticals has lagged the Nasdaq over the past year, analysts remain highly bullish about its prospects.

$NASX : 21,785.76 (-0.25%)
REGN : 751.81 (-3.27%)
AMGN : 346.31 (-1.97%)
Pfizer Stock: Is PFE Underperforming the Healthcare Sector?

Due to Pfizer’s underperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautious about the stock’s prospects

XLV : 146.45 (-0.87%)
AMGN : 346.31 (-1.97%)
PFE : 28.31 (-0.84%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two...

See More

Key Turning Points

3rd Resistance Point 361.64
2nd Resistance Point 359.32
1st Resistance Point 356.30
Last Price 346.31
1st Support Level 350.96
2nd Support Level 348.64
3rd Support Level 345.62

See More

52-Week High 391.29
Last Price 346.31
Fibonacci 61.8% 341.68
Fibonacci 50% 326.36
Fibonacci 38.2% 311.04
52-Week Low 261.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.